Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine for psychosis in opioid-dependent bipolar patients
IRCT20190905044703N1Phase 3Completed
- Sponsor
- Kerman University of Medical Sciences
- Start
- Oct 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in psychosis comparing Buprenorphine plus background medications with Placebo plus background medications (2 arms). Primary endpoints: Effect of sublingual buprenorphine in combination with other drugs on psychosis in patients, Psychosis signs at day 1 and 1 more. Started Oct 2019; status: completed.
02
Drugs
buprenorphine
03
Conditions
psychosis
Beyond the preview
Go deeper on IRCT20190905044703N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190905044703N1.